Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin
Introduction: We often treat patients with peripheral neuropathic pain due to spine diseases with mirogabalin as an alternative to pregabalin because of adverse events or insufficient efficacy associated with pregabalin treatment. However, there have been few reports on the safety and efficacy of mi...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Japanese Society for Spine Surgery and Related Research
2023-03-01
|
| Series: | Spine Surgery and Related Research |
| Subjects: | |
| Online Access: | https://www.jstage.jst.go.jp/article/ssrr/7/2/7_2022-0127/_pdf/-char/en |
| _version_ | 1797849793587838976 |
|---|---|
| author | Takuya Yamanaka Katsushi Takeshita Takao Mochizuki Hirokazu Inoue Toru Akiyama |
| author_facet | Takuya Yamanaka Katsushi Takeshita Takao Mochizuki Hirokazu Inoue Toru Akiyama |
| author_sort | Takuya Yamanaka |
| collection | DOAJ |
| description | Introduction: We often treat patients with peripheral neuropathic pain due to spine diseases with mirogabalin as an alternative to pregabalin because of adverse events or insufficient efficacy associated with pregabalin treatment. However, there have been few reports on the safety and efficacy of mirogabalin in such cases. This study aimed to evaluate the safety and efficacy of switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain due to spine diseases.
Methods: Between January 2019 and July 2021, we treated 106 patients (47 men and 59 women) with peripheral neuropathic pain due to spine diseases. All patients had switched from pregabalin to mirogabalin due to adverse events or lack of efficacy. We evaluated the retention rate, incidence of adverse events, and response rate of mirogabalin during the treatment course.
Results: The mean age of the patients was 67.5 years (range, 33-93 years), and the average dose of mirogabalin was 13.8 mg (range, 2.5-30 mg) at the final follow-up. The average duration of mirogabalin treatment was 148.7 days (range, 3-463 days). The retention rate of mirogabalin was 78.3%, the incidence of adverse events after mirogabalin administration was 28.3%, and the response rate of mirogabalin was 66%. Somnolence with pregabalin or mirogabalin administration in the mirogabalin discontinuation group was increased compared with that in the mirogabalin continuation group (pregabalin: 52.2% vs. 19.3%, mirogabalin: 26.1% vs. 7.2%). The patients who responded to mirogabalin had a lower average age, higher retention rate, and longer drug administration period than those who did not respond to it.
Conclusions: This study indicated that mirogabalin treatment might be continued in patients with peripheral neuropathic pain due to spinal diseases who could not continue pregabalin treatment. |
| first_indexed | 2024-04-09T18:49:53Z |
| format | Article |
| id | doaj.art-cab014c26d234bc692eccd17d40370dd |
| institution | Directory Open Access Journal |
| issn | 2432-261X |
| language | English |
| last_indexed | 2024-04-09T18:49:53Z |
| publishDate | 2023-03-01 |
| publisher | The Japanese Society for Spine Surgery and Related Research |
| record_format | Article |
| series | Spine Surgery and Related Research |
| spelling | doaj.art-cab014c26d234bc692eccd17d40370dd2023-04-10T01:58:19ZengThe Japanese Society for Spine Surgery and Related ResearchSpine Surgery and Related Research2432-261X2023-03-017213614110.22603/ssrr.2022-01272022-0127Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of PregabalinTakuya Yamanaka0Katsushi Takeshita1Takao Mochizuki2Hirokazu Inoue3Toru Akiyama4Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical UniversityDepartment of Orthopaedic Surgery, School of Medicine, Jichi Medical UniversityDepartment of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical UniversityDepartment of Orthopaedic Surgery, School of Medicine, Jichi Medical UniversityDepartment of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical UniversityIntroduction: We often treat patients with peripheral neuropathic pain due to spine diseases with mirogabalin as an alternative to pregabalin because of adverse events or insufficient efficacy associated with pregabalin treatment. However, there have been few reports on the safety and efficacy of mirogabalin in such cases. This study aimed to evaluate the safety and efficacy of switching from pregabalin to mirogabalin in patients with peripheral neuropathic pain due to spine diseases. Methods: Between January 2019 and July 2021, we treated 106 patients (47 men and 59 women) with peripheral neuropathic pain due to spine diseases. All patients had switched from pregabalin to mirogabalin due to adverse events or lack of efficacy. We evaluated the retention rate, incidence of adverse events, and response rate of mirogabalin during the treatment course. Results: The mean age of the patients was 67.5 years (range, 33-93 years), and the average dose of mirogabalin was 13.8 mg (range, 2.5-30 mg) at the final follow-up. The average duration of mirogabalin treatment was 148.7 days (range, 3-463 days). The retention rate of mirogabalin was 78.3%, the incidence of adverse events after mirogabalin administration was 28.3%, and the response rate of mirogabalin was 66%. Somnolence with pregabalin or mirogabalin administration in the mirogabalin discontinuation group was increased compared with that in the mirogabalin continuation group (pregabalin: 52.2% vs. 19.3%, mirogabalin: 26.1% vs. 7.2%). The patients who responded to mirogabalin had a lower average age, higher retention rate, and longer drug administration period than those who did not respond to it. Conclusions: This study indicated that mirogabalin treatment might be continued in patients with peripheral neuropathic pain due to spinal diseases who could not continue pregabalin treatment.https://www.jstage.jst.go.jp/article/ssrr/7/2/7_2022-0127/_pdf/-char/enperipheral neuropathic painspine diseasemirogabalinpregabalin |
| spellingShingle | Takuya Yamanaka Katsushi Takeshita Takao Mochizuki Hirokazu Inoue Toru Akiyama Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin Spine Surgery and Related Research peripheral neuropathic pain spine disease mirogabalin pregabalin |
| title | Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin |
| title_full | Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin |
| title_fullStr | Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin |
| title_full_unstemmed | Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin |
| title_short | Clinical Outcomes of Mirogabalin Treatment for Neuropathic Pain Due to Spinal Diseases in Patients Intolerant to Continuous Administration of Pregabalin |
| title_sort | clinical outcomes of mirogabalin treatment for neuropathic pain due to spinal diseases in patients intolerant to continuous administration of pregabalin |
| topic | peripheral neuropathic pain spine disease mirogabalin pregabalin |
| url | https://www.jstage.jst.go.jp/article/ssrr/7/2/7_2022-0127/_pdf/-char/en |
| work_keys_str_mv | AT takuyayamanaka clinicaloutcomesofmirogabalintreatmentforneuropathicpainduetospinaldiseasesinpatientsintoleranttocontinuousadministrationofpregabalin AT katsushitakeshita clinicaloutcomesofmirogabalintreatmentforneuropathicpainduetospinaldiseasesinpatientsintoleranttocontinuousadministrationofpregabalin AT takaomochizuki clinicaloutcomesofmirogabalintreatmentforneuropathicpainduetospinaldiseasesinpatientsintoleranttocontinuousadministrationofpregabalin AT hirokazuinoue clinicaloutcomesofmirogabalintreatmentforneuropathicpainduetospinaldiseasesinpatientsintoleranttocontinuousadministrationofpregabalin AT toruakiyama clinicaloutcomesofmirogabalintreatmentforneuropathicpainduetospinaldiseasesinpatientsintoleranttocontinuousadministrationofpregabalin |